Arena Pharmaceuticals Inc. (ARNA)

51.07
NASDAQ : Health Technology
Prev Close 51.19
Day Low/High 49.95 / 51.84
52 Wk Low/High 31.97 / 64.48
Avg Volume 456.50K
Exchange NASDAQ
Shares Outstanding 49.83M
Market Cap 2.55B
EPS -0.60
P/E Ratio 4.45
Div & Yield N.A. (N.A)
Today's Perilous Reversal Stock: Arena Pharmaceuticals (ARNA)

Today's Perilous Reversal Stock: Arena Pharmaceuticals (ARNA)

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a "perilous reversal" (up big yesterday but down big today) candidate

Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today

Arena Pharmaceuticals (ARNA) Showing Signs Of A Dead Cat Bounce Today

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a "dead cat bounce" (down big yesterday but up big today) candidate

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.

First Week of March 2015 Options Trading For Arena Pharmaceuticals

First Week of March 2015 Options Trading For Arena Pharmaceuticals

Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the March 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 84 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Arena Pharmaceuticals (ARNA): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators

European regulators recommended the approval of Orexigen Therapeutics weight-loss pill on Friday, opening a new commercial market opportunity closed off to the company's competitors.

Arena Pharmaceuticals (ARNA) Weak On High Volume Today

Arena Pharmaceuticals (ARNA) Weak On High Volume Today

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a weak on high relative volume candidate

Interesting ARNA Put And Call Options For July 2015

Interesting ARNA Put And Call Options For July 2015

Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the July 2015 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Super Important Biotech and Drug Stock Events for November

Super Important Biotech and Drug Stock Events for November

A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

ARNA December 12th Options Begin Trading

ARNA December 12th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the December 12th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new December 12th contracts and identified one put and one call contract of particular interest.

Arena Skimps on Data Disclosure From Weight-Loss Combo Study

Arena Skimps on Data Disclosure From Weight-Loss Combo Study

Arena Pharmaceuticals provided very little useful information Tuesday night about the Belviq-phentermine weight-loss combination.

ARNA December 5th Options Begin Trading

ARNA December 5th Options Begin Trading

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the December 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new December 5th contracts and identified one put and one call contract of particular interest.

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Interesting ARNA Put And Call Options For November 28th

Interesting ARNA Put And Call Options For November 28th

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the November 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new November 28th contracts and identified one put and one call contract of particular interest.

November 14th Options Now Available For Arena Pharmaceuticals (ARNA)

November 14th Options Now Available For Arena Pharmaceuticals (ARNA)

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the November 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new November 14th contracts and identified the following put contract of particular interest.

Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume

Arena Pharmaceuticals (ARNA) Flagged As Strong On High Volume

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a strong on high relative volume candidate

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Doc Offers Glimpse Into Arena Pharma Weight-Loss Combination Therapy

Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.

How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?

How Will Orexigen Therapeutics (OREX) Stock Respond to FDA's Contrave Approval?

Shares of Orexigen Therapeutics (OREX) were down in afternoon trading Thursday despite the FDA's approval of the company's diet pill Contrave.

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Obesity Pill is Approved and Stock Falls. Don't be Surprised

Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.

Interesting ARNA Put Options For October 31st

Interesting ARNA Put Options For October 31st

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the October 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new October 31st contracts and identified the following put contract of particular interest.

Interesting ARNA Put Options For October 24th

Interesting ARNA Put Options For October 24th

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the October 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new October 24th contracts and identified the following put contract of particular interest.

Interesting ARNA Put And Call Options For October 3rd

Interesting ARNA Put And Call Options For October 3rd

Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the October 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new October 3rd contracts and identified one put and one call contract of particular interest.

First Week of ARNA April 2015 Options Trading

First Week of ARNA April 2015 Options Trading

Investors in Arena Pharmaceuticals Inc saw new options become available this week, for the April 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arena Pharmaceuticals is Now Oversold (ARNA)

Arena Pharmaceuticals is Now Oversold (ARNA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific

'Mad Money' Lightning Round: Stay With Thermo Fisher Scientific

Cramer isn't crazy about Nimble Storage but thinks Pitney Bowes stock can go higher.

Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong

Jim Cramer's 'Mad Money' Recap: Thinking 5 Steps Ahead and Being Wrong

There are five groups of investors fighting over the direction of the markets, making for a confusing jumble of cross-currents, Cramer says.

Fed Chair Yellen Says Small Biotech Stocks Over-Valued

Fed Chair Yellen Says Small Biotech Stocks Over-Valued

Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.

Perilous Reversal Watch: Arena Pharmaceuticals (ARNA)

Perilous Reversal Watch: Arena Pharmaceuticals (ARNA)

Trade-Ideas LLC identified Arena Pharmaceuticals (ARNA) as a "perilous reversal" (up big yesterday but down big today) candidate

August 29th Options Now Available For Arena Pharmaceuticals

August 29th Options Now Available For Arena Pharmaceuticals

Investors in Arena Pharmaceuticals Inc saw new options become available today, for the August 29th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new August 29th contracts and identified the following call contract of particular interest.

TheStreet Quant Rating: C+ (Hold)